Healthy Participants
Conditions
Brief summary
The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine how the body handles IX-01.
Interventions
DRUGPlacebo
Administered orally
DRUGIX-01
Administered orally
Sponsors
Ixchelsis Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* A body mass index (Quetelet index) in the range 18-30 * Total body weight greater than (\>)50 kilograms (kg) at screening * Able to understand the nature of the trial and any hazards of participating in it * Able to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial * Participants and their partners must be willing to use adequate forms of contraception and comply with contraception requirements during the trial, and for 4 months after the last dose of medication * Must not plan to donate sperm or father a child during the trial, and for 4 months after the final dose of medication
Exclusion criteria
* Clinically relevant abnormal history, physical findings, electrocardiogram (ECG), or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the participant * Presence of acute or chronic illness or history of chronic illness sufficient to invalidate participation in the trial or make it unnecessarily hazardous * Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, haematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness * Surgery (for example (e.g.) stomach bypass) or medical condition that might affect absorption, metabolism or elimination of medicines * Presence or history of severe adverse reaction to any drug * Use of any prescription or over-the-counter medicine during the 14 days before the first dose of trial medication, or intention to use any medicine during the trial, with the exception of short courses of medication considered by the investigator not to interfere with the safety of the participant or the integrity of the trial data (such as acetaminophen (paracetamol)) * Current use of any herbal remedy or nutritional supplement, or intention to use any such product during the study * Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months * Previous participation in this trial or any other clinical trial of an oxytocin receptor antagonist * Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 5 cigarettes daily * Blood pressure and heart rate in supine position at the screening examination outside the ranges 90-130 millimeters of mercury (mm Hg) systolic, 50-90 mm Hg diastolic; heart rate 50-90 beats/minute * Possibility that the participant will not cooperate with the requirements of the protocol * Evidence of drug abuse on urine testing * Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1(HIV1) or Human Immunodeficiency Virus 2 (HIV2) * Loss of more than 400 milliliters (mL) blood during the 3 months before the trial, e.g. as a blood donor * Objection by General Practitioner (GP), on medical grounds, to participant entering trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with One or More Drug Related Adverse Events (AEs) or any Serious AEs | Baseline to Day 20 (Estimated up to 3 weeks) |
Secondary
| Measure | Time frame |
|---|---|
| Elimination Rate Constant (Kel) of IX-01 | Pre-dose up to 96 hours post dose on Day 10 |
| Apparent Clearance of IX-01 | Pre-dose up to 24 hours post dose on Day 10 |
| Apparent Volume of Distribution During the Terminal Phase of IX-01 | Pre-dose up to 96 hours post dose on Day 10 |
| Urine 6-β-hydroxycortisol/cortisol Ratio | Pre-dose on Day 1 and Day 10 |
| IX-01 Concentration and Amount Secreted in Semen | Between 2 and 4 hours after dosing, on Day 9 |
| Elimination Half Life (t1/2) of IX-01 | Pre-dose up to 96 hours post dose on Day 10 |
| Minimum Observed Concentration (Ctrough) of IX-01 | Pre-dose on Days 2 to 10 |
| Accumulation Ratio (Racc) of IX-01 based on Cmax | Pre-dose up to 24 hours post dose on Days 1 and 10 |
| Area Under the Concentration-Time Curve (AUCt) from Zero to the Time of Last Quantifiable Concentration (AUC(0-t)) of IX-01 | Pre-dose to 96 hours post dose on Day 10 |
| Peak Plasma Concentration (Cmax) of IX-01 | Pre-dose to 24 hours post dose on Days 1 and 10 |
| Area Under the Plasma Concentration-Time Curve (AUCtau) | Pre-dose up to 24 hours post dose on Days 1 and 10 |
| Time of Peak Plasma Concentration (Tmax) of IX-01 | Pre-dose to 24 hours post dose on Days 1 and 10 |
| Accumulation Ratio (Racc) of IX-01 based on AUCtau | Pre-dose up to 24 hours post dose on Day 10 |
Countries
United Kingdom
Outcome results
None listed